Effect of Synbiotic 365 on Body Composition in Overweight and Obese Individuals
NCT ID: NCT04611477
Last Updated: 2022-02-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
180 participants
INTERVENTIONAL
2020-09-28
2021-10-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Synbiotic Supplement on the Body Mass Index of Participants With Severe Obesity
NCT02958644
A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight
NCT04667377
Evaluation of Obex® in Overweight and Obesity
NCT03541005
Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Initial 6-Week Low Calorie Diet
NCT00748605
One-Year Study of S1B-509 vs Placebo for Weight Loss
NCT06517797
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
One capsule/day to be taken orally 30 minutes before breakfast
Rice Hulk
Placebo
Synbiotic365 Ver 5
One capsule/day to be taken orally 30 minutes before breakfast
Synbiotic365 Ver 5
Active Comparator
Synbiotic365 Ver 7
One capsule/day to be taken orally 30 minutes before breakfast
Synbiotic365 Ver 7
Active Comparator
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rice Hulk
Placebo
Synbiotic365 Ver 5
Active Comparator
Synbiotic365 Ver 7
Active Comparator
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Participants with a BMI in the range of ≥25 to 34.9 kg/m2.
3. Normal levels of SGOT and SGPT i.e. up to 2.5 times of upper limit of reference range.
4. Normal level of Creatinine i.e. up to 1.5 times of upper limit of reference range.
5 Alkaline Phosphatase i.e. up to 1.5 times of upper limit of reference range
6\. Participants having At least 3 of the following five metabolic risk factors: i. Waist circumference: Men: ≥ 102 cm (40.15 inches); Women ≥88 cm (34.65 inches) ii. Triglycerides levels \>150 mg/dL iii. Blood pressure ≥130 mm Hg (systolic, SBP) and/or ≥85 mm Hg(diastolic, DBP); iv. Fasting blood glucose ≥ 100 mg/ dL v. Low HDL level: Men: \< 40 mg/dL; Women: \< 50 mg/dL..
7\. Participants willing to complete all the study procedures including study-related questionnaires and comply with the study requirements.
8\. Participants willing to abstain from the restricted supplements and medications prior to inclusion and throughout the study period.
9\. Participants ready to give voluntary, written, informed consent to participate in the study.
10\. Participants willing to continue the same diet and exercise regime throughout the study period.
Exclusion:
1. Individuals having a history of smoking or currently smoking and also using any form of tobacco preparations.
2. Participants diagnosed with type II diabetes mellitus or undiagnosed cases of hyperglycemia with fasting blood sugar \> 170 mg/dl.
3. Participants with blood pressure ≥150 mm Hg (systolic, SBP) and/or ≥ 99 mm Hg (diastolic, DBP)
4. Inability to walk independently
5. History of significant weight instability (defined as \> 2 kg of weight loss over last 3 months)
6. Participants currently on diuretics, metformin or thyroid supplements. Presence of unstable, acutely symptomatic, or life-limiting illness.
7. Any significant neurological and psychiatric condition which may affect the participation and inference of the study's end points.
8 Unwillingness or inability to be randomized to any one of the three intervention groups.
9 Continuous participation in randomly assigned lifestyle intervention program for six months.
10 Bilateral hip replacements.
11 Unable to give consent.
12 Known cases of hypothyroidism.
13 Abnormal TSH value, out of reference range (\<0.4μIU/mL and \> 4.0μIU/mL).
14 Females with the history of irregular menses or any other gynecological disorder such as (polycystic ovarian syndrome (PCOS), hormonal disturbances, etc).
15 History or presence of clinically significant renal, hepatic, endocrine, biliary, gastrointestinal, pancreatic disorders, that in the judgment of the investigator, would interfere with the participant's ability to provide informed consent, comply with the study protocol (which might confound the interpretation of the study results), or put the participant at undue risk.
18 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vedic Lifesciences Pvt. Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Parag Dr. Salvi, MD
Role: PRINCIPAL_INVESTIGATOR
Shri Madhumadhav Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shri Madhumadhav Clinic
Mumbai, Maharashtra, India
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NI/190701/SYNBIOTIC365/OO
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.